神经纤维瘤病 1 型癫痫患者:人口统计学、并发症和医疗结果的综合分析。

IF 3.5 3区 医学 Q1 DERMATOLOGY Experimental Dermatology Pub Date : 2024-11-06 DOI:10.1111/exd.70011
Nilesh Kodali, Audrey Terrany, Keshav D. Kumar, Shae Chambers, Shivkar Amara, Robert A. Schwartz
{"title":"神经纤维瘤病 1 型癫痫患者:人口统计学、并发症和医疗结果的综合分析。","authors":"Nilesh Kodali,&nbsp;Audrey Terrany,&nbsp;Keshav D. Kumar,&nbsp;Shae Chambers,&nbsp;Shivkar Amara,&nbsp;Robert A. Schwartz","doi":"10.1111/exd.70011","DOIUrl":null,"url":null,"abstract":"<p>Neurofibromatosis Type 1 (NF1) is the most common neurocutaneous disorder in the United States. Due to a nonfunctional mutation in the NF1 gene, the disorder may initially present with café-au-lait spots and later numerous neurofibromas across the body. Epilepsy is a rare comorbidity of NF1, with an incidence of just 4%–7%. While abnormal electroencephalograms have been seen in up to 25% of NF1 patients, very few studies have investigated the association between epilepsy and the NF1 patient profile. This study was aimed at evaluating the associations between epilepsy and demographics, comorbidities and healthcare outcomes in NF1 patients. The 2017 National Inpatient Sample (NIS) database was retrospectively queried for patients with NF1 using ICD-10 PCS codes. Chi-square tests were used in univariable analysis to compare patients within this cohort with and without epilepsy. Regression analysis was used in multivariable analysis to identify comorbidities that were predictors of epilepsy and the effect of comorbidities on outcomes. 4635 patients with NF1 were identified, of which 655 (14.1%) had epilepsy and 3980 (85.9%) did not. The NF1 patient population with epilepsy was largely comprised of White males of lower household income in larger urban/teaching hospitals and who used Medicare or Medicaid. Multivariable logistic regression revealed that malignant brain neoplasms, paralytic ileus, scoliosis, pregnancy complications, paralysis, other neurological disorders, metastatic cancer, coagulopathy, drug abuse and hypertension were predictors of developing epilepsy in NF1 patients. Additionally, epilepsy in NF1 patients was associated with a shorter length of stay, lower total charges and fewer total procedures.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/exd.70011","citationCount":"0","resultStr":"{\"title\":\"Neurofibromatosis Type 1 Patients With Epilepsy: A Comprehensive Analysis of Demographics, Comorbidities and Healthcare Outcomes\",\"authors\":\"Nilesh Kodali,&nbsp;Audrey Terrany,&nbsp;Keshav D. Kumar,&nbsp;Shae Chambers,&nbsp;Shivkar Amara,&nbsp;Robert A. Schwartz\",\"doi\":\"10.1111/exd.70011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Neurofibromatosis Type 1 (NF1) is the most common neurocutaneous disorder in the United States. Due to a nonfunctional mutation in the NF1 gene, the disorder may initially present with café-au-lait spots and later numerous neurofibromas across the body. Epilepsy is a rare comorbidity of NF1, with an incidence of just 4%–7%. While abnormal electroencephalograms have been seen in up to 25% of NF1 patients, very few studies have investigated the association between epilepsy and the NF1 patient profile. This study was aimed at evaluating the associations between epilepsy and demographics, comorbidities and healthcare outcomes in NF1 patients. The 2017 National Inpatient Sample (NIS) database was retrospectively queried for patients with NF1 using ICD-10 PCS codes. Chi-square tests were used in univariable analysis to compare patients within this cohort with and without epilepsy. Regression analysis was used in multivariable analysis to identify comorbidities that were predictors of epilepsy and the effect of comorbidities on outcomes. 4635 patients with NF1 were identified, of which 655 (14.1%) had epilepsy and 3980 (85.9%) did not. The NF1 patient population with epilepsy was largely comprised of White males of lower household income in larger urban/teaching hospitals and who used Medicare or Medicaid. Multivariable logistic regression revealed that malignant brain neoplasms, paralytic ileus, scoliosis, pregnancy complications, paralysis, other neurological disorders, metastatic cancer, coagulopathy, drug abuse and hypertension were predictors of developing epilepsy in NF1 patients. Additionally, epilepsy in NF1 patients was associated with a shorter length of stay, lower total charges and fewer total procedures.</p>\",\"PeriodicalId\":12243,\"journal\":{\"name\":\"Experimental Dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/exd.70011\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/exd.70011\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/exd.70011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

神经纤维瘤病 1 型(NF1)是美国最常见的神经皮肤疾病。由于 NF1 基因发生了非功能性突变,这种疾病最初可能表现为咖啡斑,随后全身会出现许多神经纤维瘤。癫痫是 NF1 的罕见并发症,发病率仅为 4%-7%。虽然高达 25% 的 NF1 患者会出现异常脑电图,但很少有研究调查癫痫与 NF1 患者特征之间的关联。本研究旨在评估 NF1 患者的癫痫与人口统计学、合并症和医疗结果之间的关联。研究人员使用 ICD-10 PCS 编码对 2017 年全国住院患者样本(NIS)数据库中的 NF1 患者进行了回顾性查询。在单变量分析中使用了卡方检验来比较队列中患有和不患有癫痫的患者。回归分析用于多变量分析,以确定可预测癫痫的合并症以及合并症对预后的影响。共发现4635名NF1患者,其中655人(14.1%)患有癫痫,3980人(85.9%)未患癫痫。患有癫痫的NF1患者主要是在较大的城市/教学医院就诊的家庭收入较低的白人男性,他们使用医疗保险或医疗补助。多变量逻辑回归显示,恶性脑肿瘤、麻痹性回肠炎、脊柱侧弯、妊娠并发症、瘫痪、其他神经系统疾病、转移性癌症、凝血功能障碍、药物滥用和高血压是NF1患者罹患癫痫的预测因素。此外,NF1患者的癫痫与住院时间较短、总费用较低和总手术次数较少有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Neurofibromatosis Type 1 Patients With Epilepsy: A Comprehensive Analysis of Demographics, Comorbidities and Healthcare Outcomes

Neurofibromatosis Type 1 (NF1) is the most common neurocutaneous disorder in the United States. Due to a nonfunctional mutation in the NF1 gene, the disorder may initially present with café-au-lait spots and later numerous neurofibromas across the body. Epilepsy is a rare comorbidity of NF1, with an incidence of just 4%–7%. While abnormal electroencephalograms have been seen in up to 25% of NF1 patients, very few studies have investigated the association between epilepsy and the NF1 patient profile. This study was aimed at evaluating the associations between epilepsy and demographics, comorbidities and healthcare outcomes in NF1 patients. The 2017 National Inpatient Sample (NIS) database was retrospectively queried for patients with NF1 using ICD-10 PCS codes. Chi-square tests were used in univariable analysis to compare patients within this cohort with and without epilepsy. Regression analysis was used in multivariable analysis to identify comorbidities that were predictors of epilepsy and the effect of comorbidities on outcomes. 4635 patients with NF1 were identified, of which 655 (14.1%) had epilepsy and 3980 (85.9%) did not. The NF1 patient population with epilepsy was largely comprised of White males of lower household income in larger urban/teaching hospitals and who used Medicare or Medicaid. Multivariable logistic regression revealed that malignant brain neoplasms, paralytic ileus, scoliosis, pregnancy complications, paralysis, other neurological disorders, metastatic cancer, coagulopathy, drug abuse and hypertension were predictors of developing epilepsy in NF1 patients. Additionally, epilepsy in NF1 patients was associated with a shorter length of stay, lower total charges and fewer total procedures.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Experimental Dermatology
Experimental Dermatology 医学-皮肤病学
CiteScore
6.70
自引率
5.60%
发文量
201
审稿时长
2 months
期刊介绍: Experimental Dermatology provides a vehicle for the rapid publication of innovative and definitive reports, letters to the editor and review articles covering all aspects of experimental dermatology. Preference is given to papers of immediate importance to other investigators, either by virtue of their new methodology, experimental data or new ideas. The essential criteria for publication are clarity, experimental soundness and novelty. Letters to the editor related to published reports may also be accepted, provided that they are short and scientifically relevant to the reports mentioned, in order to provide a continuing forum for discussion. Review articles represent a state-of-the-art overview and are invited by the editors.
期刊最新文献
Disabled 2 (Dab2) Regulates Tumour Progression in Skin Squamous Cell Carcinoma Neurofibromatosis Type 1 Patients With Epilepsy: A Comprehensive Analysis of Demographics, Comorbidities and Healthcare Outcomes Incontinence-Associated Dermatitis-Like Skin Changes Induced by the Application of Absorbent Pads Containing Bacteria and Artificial Urine in Rats NEDD4L Inhibits the Proliferation and Migration of Keloid Fibroblasts by Regulating YY1 Ubiquitination-Mediated Glycolytic Metabolic Reprogramming Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1